Market Place
Sourcing Support
Kala Pharmaceuticals Announces Name Change to KALA BIO
02 Aug 2023 //
GLOBENEWSWIRE
Kala Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Jul 2023 //
GLOBENEWSWIRE
Kala Pharma Reports Inducement Grants Under Nasdaq Listing Rule
23 Jun 2023 //
GLOBENEWSWIRE
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
Kala Pharmaceuticals Reports1Q 2023 FYR and Provides Corporate Update
09 May 2023 //
GLOBENEWSWIRE
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012
12 Apr 2023 //
GLOBENEWSWIRE
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
29 Mar 2023 //
GLOBENEWSWIRE
Kala Announces Positive Update from Phase 2b Trial Evaluating KPI-012
27 Mar 2023 //
PRESS RELEASE
Kala Announces Safety Update from CHASE Ph2b Trial Evaluating KPI-012
27 Mar 2023 //
GLOBENEWSWIRE
Kala Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
08 Mar 2023 //
PRESS RELEASE
Kala Reports Fourth Quarter and Full Year 2022 Financial Results
03 Mar 2023 //
BIOSPACE
Kala Pharmaceuticals falls after up to $40M shares sale announcement
20 Jan 2023 //
SEEKING ALPHA
Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher
28 Dec 2022 //
BENZINGA
Kala Pharma Announces FDA Acceptance of IND Application for KPI-012 for PCED
28 Dec 2022 //
GLOBENEWSWIRE
Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
28 Nov 2022 //
GLOBENEWSWIRE
Kala Pharma Announces Submission of Investigational NDA for KPI-012
28 Nov 2022 //
GLOBENEWSWIRE
Kala Reports3Q 2022 Financial Results and Provides Corporate Update
08 Nov 2022 //
GLOBENEWSWIRE
Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to itsBOD
01 Nov 2022 //
GLOBENEWSWIRE
Kala Pharmaceuticals Announces Reverse Stock Split
20 Oct 2022 //
GLOBENEWSWIRE
Kala Pharmaceuticals to Present at H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Kala Pharma Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
19 Aug 2022 //
GLOBENEWSWIRE
Kala Announces Distribution of Preferred Stock to Holders of its Common Stock
18 Aug 2022 //
GLOBENEWSWIRE
Kala Pharmaceuticals Reports Q2 2022 Rusult and Provides Corporate Update
11 Aug 2022 //
GLOBENEWSWIRE
Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August
04 Aug 2022 //
GLOBENEWSWIRE
Kala Pharma Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
22 Jul 2022 //
GLOBENEWSWIRE
Kala Pharmaceuticals Completes Sale of EYSUVIS and INVELTYS to Alcon Inc
11 Jul 2022 //
GLOBENEWSWIRE
Kala Pharma Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
17 Jun 2022 //
GLOBENEWSWIRE
Kala buys time by selling eye disease drugs to Alcon for $60M
24 May 2022 //
FIERCEPHARMA
Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio
24 May 2022 //
BIOSPACE
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update
16 May 2022 //
BIOSPACE
Kala Pharmaceuticals to Report First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS
03 May 2022 //
GLOBENEWSWIRE
Kala Pharmaceuticals to Present Clinical Data for KPI-012 at ARVO
01 May 2022 //
GLOBENEWSWIRE
Kala Pharma to Present Phase 1b Data for KPI-012 in PCED at 2022 ARVO
04 Apr 2022 //
GLOBENEWSWIRE
Kala Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
Kala Pharma to Report Fourth Quarter and Full Year 2021 Financial Results
23 Mar 2022 //
GLOBENEWSWIRE
Kala Pharma says EYSUVIS Now Covered on UnitedHealthcare and Cigna Medicare
08 Mar 2022 //
GLOBENEWSWIRE
Kala Pharma Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
18 Feb 2022 //
GLOBENEWSWIRE
Kala Pharma Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
17 Dec 2021 //
GLOBENEWSWIRE
Kala Pharmaceuticals acquires regenerative biotherapy developer Combangio
16 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
Kala Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel
15 Nov 2021 //
GLOBENEWSWIRE
Kala Pharmaceuticals Acquires Combangio
15 Nov 2021 //
BIOSPACE
Eye disease specialists venture into M&A with a buyout deal worth up to $126M
15 Nov 2021 //
ENDPTS
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635
18 Aug 2021 //
GLOBENEWSWIRE
Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August
04 Aug 2021 //
GLOBENEWSWIRE
Kala Pharma Second Quarter 2021 Financial Results and Host Conference Call
29 Jul 2021 //
GLOBENEWSWIRE
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635
21 Jun 2021 //
BUSINESSWIRE
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing
18 Jun 2021 //
BUSINESSWIRE
Kala Pharma Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
18 Mar 2021 //
BUSINESSWIRE
Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna
16 Mar 2021 //
BUSINESSWIRE
Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna
16 Mar 2021 //
BUSINESSWIRE
Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts
16 Feb 2021 //
BUSINESSWIRE
Kala Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease
07 Jan 2021 //
BUSINESSWIRE
Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment
07 Jan 2021 //
BUSINESSWIRE
Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM
16 Nov 2020 //
BUSINESSWIRE
Once rejected, Kala`s dry eye drug now gains entry in field Novartis is grooming
28 Oct 2020 //
ENDPTS
Kala’s dry eye syndrome steroid likely to be FDA approved; mixed potential
12 Oct 2020 //
CLINICALTRIALSARENA
Kala Announces FDA Acceptance of NDA for EYSUVIS™ for Dry Eye Disease
26 May 2020 //
BUSINESSWIRE
